150 related articles for article (PubMed ID: 36978470)
21. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates.
Piewngam P; Kiratisin P
Int J Antimicrob Agents; 2014 Nov; 44(5):396-401. PubMed ID: 25442358
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Agar Dilution to Broth Microdilution for Testing
Albano M; Karau MJ; Schuetz AN; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32967901
[TBL] [Abstract][Full Text] [Related]
25. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):321-325. PubMed ID: 31029489
[TBL] [Abstract][Full Text] [Related]
26. Rapid cefiderocol NP test for detection of cefiderocol susceptibility/resistance in Enterobacterales.
Nordmann P; Bouvier M; Poirel L; Sadek M
J Antimicrob Chemother; 2022 Nov; 77(12):3456-3461. PubMed ID: 36226737
[TBL] [Abstract][Full Text] [Related]
27.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
28. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
[TBL] [Abstract][Full Text] [Related]
29.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
[TBL] [Abstract][Full Text] [Related]
30. Polymyxin B Etest
Kulengowski B; Ribes JA; Burgess DS
Clin Microbiol Infect; 2019 Jan; 25(1):92-95. PubMed ID: 29674129
[TBL] [Abstract][Full Text] [Related]
31. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
32. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of
García-Fernández S; Bala Y; Armstrong T; García-Castillo M; Burnham CA; Wallace MA; Hardy D; Zambardi G; Cantón R
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31597745
[TBL] [Abstract][Full Text] [Related]
33.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
35. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
Ghebremedhin B; Ahmad-Nejad P
Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
[TBL] [Abstract][Full Text] [Related]
36. In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales.
Ozyurt OK; Tufanoglu P; Cetinkaya O; Ozhak B; Yazisiz H; Ongut G; Turhan O; Ogunc D
Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649528
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
38. Inter-technique variability between antimicrobial susceptibility testing methods affects clinical classification of cefuroxime in strains close to breakpoint.
Ballestero-Téllez M; Jiménez-Morgades E; Arjona-Camacho P; Blanco-Suárez A; Padilla-Esteba E; Pérez-Jové J
Clin Microbiol Infect; 2020 May; 26(5):648.e1-648.e3. PubMed ID: 31972319
[TBL] [Abstract][Full Text] [Related]
39. Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of
Ballesté-Delpierre C; Ramírez Á; Muñoz L; Longshaw C; Roca I; Vila J
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203791
[TBL] [Abstract][Full Text] [Related]
40. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
